741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies

• Omid Hamid,
• Siqing Fu,
• Manish Sharma,
• Anna Spreafico,
• Kyriakos P Papadopoulos,
• Erika Hamilton,
• Alexander Spira,
• Quincy Chu,
• Brigette Ma,
• Emily Roberts-Thomson,
• Dih-Yih Chen,
• Judy S Wang,
• Scott A Laurie,
• Mark R Bray,
• Roger Sidhu

Affiliations

Omid Hamid

5The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA

Siqing Fu

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Manish Sharma

3START Midwest, Grand Rapids, MI, USA

Anna Spreafico

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Kyriakos P Papadopoulos

Aff1 grid.477989.c0000000404347503South Texas Accelerated Research Therapeutics (START) San Antonio TX USA

Erika Hamilton

5Sarah Cannon Research Institute, Nashville, TN, USA

Alexander Spira

Department of Medical Oncology, Virginia Cancer Specialists, Fairfax, Virginia, USA

Quincy Chu

Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada

Brigette Ma

7The Chinese University of Hong Kong, Sha Tin, Hong Kong

Emily Roberts-Thomson

9Treadwell Therapeutics, Toronto, Canada

Dih-Yih Chen

11Treadwell Therapeutics, Toronto, Canada

Judy S Wang

9Florida Cancer Specialists/SCRI, Sarasota, FL, USA

Scott A Laurie

2The Ottawa Hospital Cancer Center, Ottawa, ON, Canada

Mark R Bray

11Treadwell Therapeutics, Toronto, ON, Canada

Roger Sidhu

12Treadwell Therapeutics Inc, New York, NY, USA